Dr. Laskin’s clinical and research interests have primarily focused around lung and head and neck cancers, and in recent years, her research has evolved towards genomic and personalized medicine.
Dr. Laskin is the co-founder and clinical leader of the Personalized OncoGenomics (POG) program, a translational research effort that uses in-depth genomic sequencing to guide chemotherapy decision-making in a clinically relevant time-frame.